Cancer Advance
Date: Location: Cost:
April 11, 2017 Harvard Medical School - Joseph B. Martin Conference Center
77 Avenue Louis Pasteur
Boston, MA 02115

Starting at $1950

 

Dress Code:
Business Attire

Register

Cancer Advance Boston - April 11, 2017

Co-hosts: Jörn Aldag, Robert Bazemore, Paul Biondi, Pablo Cagnoni, Chip Clark, George Demetri, Giulio Draetta, Robert Forrester, Edward Garmey, Chris Guiffre, JC Gutierrez-Ramos, John Herrmann, Arthur Krieg, Jonathan Lewis, Ferran Prat, Bob Silverman, Kristine Swiderek, Daniel Teper, Pascal Touchon, Beth Trehu, Markus Warmuth

Time Agenda
7:00-8:00 am

Registration and Networking Breakfast

7:45-8:00 am

Welcome and Opening Remarks

8:00-8:45 am

Oncology 2017: Trends to Watch
Denise Faustman, Director of Immunobiology, Massachusetts General Hospital; John Hohneker, EVP & Head, R&D, FORMA Therapeutics; Niven Narain, Co-Founder, President, & CEOBerg; James Oliviero, President & CEO, Checkpoint Therapeutics; Maria Whitman, Managing Partner, ZS Associates
Moderator: Robert Forrester, President & CEO, Verastem

8:45-9:15 am

Financing Innovation in the Oncology Market
Carolyn Green, Executive Director, Strategic InvestmentsPfizer; John Haurum, CEO, F-Star Biotechnology; Martin Lehr, President & CBO, Context Therapeutics; Jonathan Lewis, CEO, Samus Therapeutics; Thilo Schroeder, PartnerNextech Invest 
Moderator: Pablo Cagnoni, President & CEO, Tizona Therapeutics

9:15-9:45 am

Optimizing Value to Drive Reimbursement
Jim Coccia
VP, US Market Access, Oncology, Takeda; Richard Popiel, EVP & CMO, Regence BlueCross BlueShield

9:45-10:05 am

Fireside Chat

10:05-10:35 am

Networking Break

10:35-11:05 am

Leveraging Liquid Biopsies and New Technologies
Richard Lanman
CMO, Guardant Health; Jimmy Lin, CSO, Oncology, Natera
Moderator: George Demetri, SVP, Experimental Therapeutics, Dana Farber Cancer Institute

11:05-11:35 am

Novel Clinical Trial Design: Implementing Biomarkers and Diagnostics
Giulio Draetta, Director, Institute for Applied Cancer Science, MD Anderson Cancer Center; Rachel Humphrey, CMO, CytomX; Oliver Rosen, CMO, Deciphera; Peter Smith, VP, Drug Discovery Biology, H3 Biomedicine; Beth Trehu, CMO, Jounce Therapeutics
Moderator: Edward GarmeyCMO, Bicycle Therapeutics

11:35-12:05 pm

Innovative Deal Structures in Oncology
Andrew Curtis, Head of Strategy, Affimed Therapeutics AG; John DeYoung, VP, Worldwide BD, Pfizer; Shalabh Gupta, President & CEO, Globavir Biosciences; Robert Radinsky, VP, Oncology Scientific Innovation, Janssen Research & Development; Guillaume VignonHead of Immuno-Oncology Licensing & BD, Merck KGaA
Moderator: Bob SilvermanHead, Externalized Drug Discovery Partnering, Roche

12:05-1:15 pm

Networking Lunch 

1:15-1:45 pm

Maximizing Tech Transfer

1:45-2:15 pm

Commercialization and Manufacturing: Strategies for Success
Pascal Touchon
SVP Global Head, Strategy & BD, Novartis Oncology

2:15-2:45 pm

Immunotherapy Trends & Challenges
Sudhir Agrawal, President, Research, Idera Pharmaceuticals; Chip Clark, President & CEO, Genocea Biosciences; Pamela Contag, CEO, ConcentRx Inc.; Björn Frendéus, CSO, BioInvent; Kristine Swiderek, CSO, OncoResponse
Moderator: Jonathan PachterCSO, Verastem

2:45-3:10 pm

Networking Break

3:10-3:40 pm

Advances in Combination Therapy
Errik Anderson, Co-Founder, President & COOCompass Therapeutics; Jeffrey BachaPresident, CEO, & Co-Founder, DelMar Pharmaceuticals; Steven Fruchtman, CMO, Onconova; Arthur Krieg, Founder & CEO, Checkmate Pharmaceuticals; Patrick Tricoli, CEO, Nanobiotix USA
Moderator: Ferran Prat, VP, Strategic Industry Ventures, MD Anderson Cancer Center

3:40-4:10 pm

Partnering and M&A Outlook
Paul Biondi, SVP, Head, BD, Bristol-Myers Squibb; David Giljohann, CEO, Exicure; Jim HealyManaging General Partner, Sofinnova Ventures; Henning Steinhagen, EVP, Discovery & Development, Aptuit; Daniel Teper, CEO, Immune Pharmaceuticals
Moderator: Justin Renz, EVP, CFO, & Treasurer, Karyopharme

4:10-4:40 pm

The Next 10 Years: Predictions and Wishes
Jörn Aldag, CEO, Hookipa Biotech AG; Andrew Allen, President & CEO, Gritstone Oncology; Robert Bazemore, President & CEO, Epizyme; JC Guitierrez-Ramos, CEO, Synlogic Therapeutics; John Herrmann, Expert Partner & SVP, OncologyCatenion
Moderator: Tim Clackson, CSO and President of R&D, ARIAD 

4:40-5:00 pm

Presentation of the Oncology Innovation of the Year Award

5:00-6:00 pm

Networking Cocktails and Hors d'oeuvres

Premier Sponsors: (see all sponsors)

<